Celgene’s Pomalyst Wins FDA OK for Advanced Multiple Myeloma, Can Only Be Dispensed Via REMS Program

Drug Industry Daily
A A
The FDA has approved Celgene’s Pomalyst for patients with multiple myeloma whose disease progressed after treatment with other cancer drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily